Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Overall MarketRank^™

2.19 out of 5 stars

Medical Sector

27th out of 2,042 stocks

Pharmaceutical Preparations Industry

11th out of 770 stocks

2.4 Analyst's Opinion

Consensus Rating
Merck & Co., Inc. has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $97.50, Merck & Co., Inc. has a forecasted upside of 24.3% from its current price of $78.41.
Amount of Analyst Coverage
Merck & Co., Inc. has only been the subject of 1 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Merck & Co., Inc. has received 868 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Merck & Co., Inc. has received 839 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Merck & Co., Inc. has received 50.85% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Merck & Co., Inc. and other stocks. Vote “Outperform” if you believe MRK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Yield
Merck & Co., Inc. pays a meaningful dividend of 3.34%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Merck & Co., Inc. has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of Merck & Co., Inc. is 50.10%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 42.83% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Merck & Co., Inc. insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.28% of the stock of Merck & Co., Inc. is held by insiders.
Percentage Held by Institutions
72.86% of the stock of Merck & Co., Inc. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Merck & Co., Inc. are expected to grow by 2.88% in the coming year, from $5.90 to $6.07 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Merck & Co., Inc. is 17.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.28.
Price to Earnings Ratio vs. Sector
The P/E ratio of Merck & Co., Inc. is 17.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 44.11.
Price to Earnings Growth Ratio
Merck & Co., Inc. has a PEG Ratio of 1.89. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Merck & Co., Inc. has a P/B Ratio of 7.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

Is Merck & Co., Inc. a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Merck & Co., Inc. stock.
View analyst ratings for Merck & Co., Inc. or view top-rated stocks.

What stocks does MarketBeat like better than Merck & Co., Inc.?

Wall Street analysts have given Merck & Co., Inc. a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Merck & Co., Inc. wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Merck & Co., Inc.?

Merck & Co., Inc. saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 23,740,000 shares, an increase of 30.9% from the March 15th total of 18,140,000 shares. Based on an average trading volume of 11,960,000 shares, the short-interest ratio is currently 2.0 days. Currently, 0.9% of the company's shares are sold short.
View Merck & Co., Inc.'s Short Interest.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Friday, July 30th 2021.
View our earnings forecast for Merck & Co., Inc..

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) posted its earnings results on Thursday, April, 29th. The company reported $1.40 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $1.63 by $0.23. The business earned $12.08 billion during the quarter, compared to analyst estimates of $12.71 billion. Merck & Co., Inc. had a trailing twelve-month return on equity of 53.83% and a net margin of 24.33%. The business's revenue for the quarter was up .2% compared to the same quarter last year. During the same period last year, the firm earned $1.50 EPS.
View Merck & Co., Inc.'s earnings history.

How has Merck & Co., Inc.'s stock been impacted by Coronavirus?

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MRK stock has decreased by 1.1% and is now trading at $78.41.
View which stocks have been most impacted by COVID-19.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. declared a quarterly dividend on Wednesday, January 27th. Shareholders of record on Monday, March 15th will be paid a dividend of $0.65 per share on Wednesday, April 7th. This represents a $2.60 dividend on an annualized basis and a yield of 3.32%. The ex-dividend date of this dividend is Friday, March 12th.
View Merck & Co., Inc.'s dividend history.

Is Merck & Co., Inc. a good dividend stock?

Merck & Co., Inc. pays an annual dividend of $2.60 per share and currently has a dividend yield of 3.34%. Merck & Co., Inc. does not yet have a strock track record of dividend growth. The dividend payout ratio of Merck & Co., Inc. is 50.10%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 42.83% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.
View Merck & Co., Inc.'s dividend history.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. updated its FY 2021 earnings guidance on Thursday, May, 6th. The company provided EPS guidance of 6.480-6.680 for the period, compared to the Thomson Reuters consensus estimate of $6.570. The company issued revenue guidance of $51.80 billion-$53.80 billion, compared to the consensus revenue estimate of $52.51 billion.

What price target have analysts set for MRK?

10 Wall Street analysts have issued 12 month target prices for Merck & Co., Inc.'s shares. Their forecasts range from $88.00 to $105.00. On average, they anticipate Merck & Co., Inc.'s stock price to reach $97.50 in the next year. This suggests a possible upside of 24.3% from the stock's current price.
View analysts' price targets for Merck & Co., Inc. or view top-rated stocks among Wall Street analysts.

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the following people:

Mr. Kenneth C. Frazier, CEO & Chairman (Age 66, Pay $4.3M)
Mr. Robert M. Davis, Pres (Age 54, Pay $2.29M)
Ms. Jennifer L. Zachary, Exec. VP, Gen. Counsel & Corp. Sec. (Age 43, Pay $1.79M)
Mr. Sanat Chattopadhyay, Exec. VP & Pres of Merck Manufacturing Division (Age 61, Pay $1.56M)
Ms. Caroline Litchfield, Exec. VP & CFO
Mr. David Michael Williams, Chief Information & Digital Officer
Mr. Peter Dannenbaum CFA, VP of Investor Relations
Michael W. Fleming, Sr. VP and Chief Ethics & Compliance Officer (Age 62)
Ms. Jennifer Mauer, VP of Global Communications
Mr. Steven C. Mizell, Exec. VP & Chief HR Officer (Age 61)

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

1,343 employees have rated Merck & Co., Inc. CEO Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among Merck & Co., Inc.'s employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Merck & Co., Inc.'s key competitors?

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of MRK's competitors.

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), The Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and The Home Depot (HD).

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.66%), Swiss National Bank (0.42%), Fisher Asset Management LLC (0.39%), LSV Asset Management (0.38%), The PNC Financial Services Group Inc. (0.36%) and Sumitomo Mitsui Trust Holdings Inc. (0.36%). Company insiders that own Merck & Co., Inc. stock include Frank Clyburn, Julie L Gerberding, Richard R Deluca, Robert M Davis, Sanat Chattopadhyay and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc..

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of Nova Scotia, Cibc World Markets Corp, Ferguson Wellman Capital Management Inc., Conning Inc., The Manufacturers Life Insurance Company , Los Angeles Capital Management LLC, and Unigestion Holding SA. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Julie L Gerberding, Robert M Davis, and Sanat Chattopadhyay.
View insider buying and selling activity for Merck & Co., Inc. or view top insider-selling stocks.

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Smead Capital Management Inc., GSB Wealth Management LLC, Sarasin & Partners LLP, NN Investment Partners Holdings N.V., Wesbanco Bank Inc., Robeco Institutional Asset Management B.V., and D.A. Davidson & CO..
View insider buying and selling activity for Merck & Co., Inc. or or view top insider-buying stocks.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $78.41.

How much money does Merck & Co., Inc. make?

Merck & Co., Inc. has a market capitalization of $198.41 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis.

How many employees does Merck & Co., Inc. have?

Merck & Co., Inc. employs 73,000 workers across the globe.

When was Merck & Co., Inc. founded?

Merck & Co., Inc. was founded in 1891.

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is www.merck.com.

Where are Merck & Co., Inc.'s headquarters?

Merck & Co., Inc. is headquartered at 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]

This page was last updated on 5/9/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Merck & Co., Inc. Stock Forecast, Price & News

Adding

Adding

Adding Merck & Co., Inc.

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links

Headlines

About Merck & Co., Inc.

MarketRank™

Overall MarketRank™